Differential diagnosis of bladder versus colorectal adenocarcinoma: keratin 7 and GATA3 positivity in nuclear ß-catenin-negative glandular tumours defines adenocarcinoma of the bladder

Broede, Anna; Oll, Matthias; Maurer, Angela; Siegert, Sabine; Stoerkel, S.; Golz, Reinhard; Schwamborn, Kristina; Veeck, Jürgen; Knuechel, Ruth; Gaisa, Nadine T.

doi:10.1136/jclinpath-2015-203144

Cited by 20 publications

(19 citation statements)

References 21 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BAC can exhibit various phenotypes: enteric/colonic, mucinous/colloid, signet-ring cell, clear cell, hepatoid, mixed and adenocarcinoma not otherwise specified (NOS; if without a specific glandular growth pattern) [5]. This phenotypical diversity turns them into diagnostically challenging tumours, since-first of all-metastatic carcinomas must be excluded [6].…”

Section: Introductionmentioning

confidence: 99%

Comparative genomic profiling of glandular bladder tumours

et al. 2020

Self Cite

View full text Add to dashboard Cite

Primary glandular bladder tumours (bladder adenocarcinoma [BAC], urachal adenocarcinoma [UAC], urothelial carcinoma with glandular differentiation [UCg]) are rare malignancies with histological resemblance to colorectal adenocarcinoma (CORAD) in the majority of this subgroup. Definite case numbers are very low, molecular data are limited and the pathogenesis remains poorly understood. Therefore, this study was designed to complement current knowledge by in depth analysis of BAC (n = 12), UAC (n = 13), UCg (n = 11) and non-invasive glandular lesions (n = 19). In BAC, in addition to known alterations in TP53, Wnt, MAP kinase and MTOR pathway, mutations in SMAD4, ARID1A and BRAF were identified. Compared to published data on muscle invasive bladder cancer (BLCA) and CORAD, UCg exhibited frequent "urothelial" like alterations while BAC and UAC were characterised by a more "colorectal" like mutational pattern. Immunohistochemically, there was no evidence of DNA mismatch repair deficiency or PD-L1 tumour cell positivity in any sample. Depending on the used antibody 0-45% of BAC, 0-30% of UCg and 0% UAC cases exhibited PD-L1 expressing tumour associated immune cells. A single BAC (9%, 1/11) showed evidence of ARID1A protein loss, and two cases of UCg (20%, 2/10) showed loss of SMARCA1 and PBRM1, respectively. Taken together, our data suggest at least in part involvement of similar pathways driving tumourigenesis of adenocarcinomas like BAC, UAC and CORAD independent of their tissue origin. Alterations of TERT and FBXW7 in single cases of intestinal metaplasia further point towards a possible precancerous character in line with previous reports.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparative genomic profiling of glandular bladder tumours

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Another diagnostic scenario that can be periodically challenging is the distinction between CRC and primary bladder adenocarcinoma, particularly as the latter can show CDX2 expression . It has been suggested that β‐catenin immunohistochemistry (nuclear decoration seen only in CRC) may help in making this distinction, but whether A33 may also aid in this distinction should be investigated next. Finally, larger cohorts of CRC from other centres should also be studied with A33, particularly to confirm the immunomarker's sensitivity, especially in biopsy material.…”

Section: Discussionmentioning

confidence: 99%

A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A number of immunomarkers have been tested in this regard, which include CK7, CK20, CDX2, villin, thrombomodulin, a-methylacyl coenzyme-A racemase, carcinoembryonic antigen (CEA), GATA3, p63, CDH17, bcatenin, and many others. [51][52][53][54][55][56] Among all tested markers, bcatenin is the only one that can be reliably used to aid in the distinction. Specifically, nuclear b-catenin expression is detected in more than 80% of CRCs but has never been seen in primary adenocarcinoma of the bladder.…”

Section: 48mentioning

confidence: 99%

“…Specifically, nuclear b-catenin expression is detected in more than 80% of CRCs but has never been seen in primary adenocarcinoma of the bladder. 51,55,56 Instead, bladder adenocarcinomas show only membranous staining. Thus, membranous b-catenin staining will not help, but nuclear staining indicates a colorectal origin.…”

Section: 48mentioning

confidence: 99%

Practical Immunohistochemistry in Neoplastic Pathology of the Gastrointestinal Tract, Liver, Biliary Tract, and Pancreas

Wang¹,

Kim²,

Koo³

et al. 2017

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— Immunomarkers with diagnostic, therapeutic, or prognostic values have been increasingly used to maximize the benefits of clinical management of patients with neoplastic diseases of the gastrointestinal tract, liver, biliary tract, and pancreas. Objectives.— To review the characteristics of immunomarkers that are commonly used in surgical pathology practice for neoplasms of the gastrointestinal tract, liver, biliary tract, and pancreas, and to summarize the clinical usefulness of immunomarkers that have been discovered in recent years in these fields. Data Sources.— Data sources include literature review, authors' research data, and personal practice experience. Conclusions.— Immunohistochemistry is an indispensable tool for the accurate diagnosis of neoplastic diseases of the gastrointestinal tract, liver, biliary tract, and pancreas. Useful immunomarkers are available to help distinguish malignant neoplasms from benign conditions, determine organ origins, and subclassify neoplasms that are morphologically and biologically heterogeneous. Specific immunomarkers are also available to help guide patient treatment and assess disease aggressiveness, which are keys to the success of personalized medicine. Pathologists will continue to play a critical role in the discovery, validation, and application of new biomarkers, which will ultimately improve patient care.

show abstract

Differential diagnosis of bladder versus colorectal adenocarcinoma: keratin 7 and GATA3 positivity in nuclear ß-catenin-negative glandular tumours defines adenocarcinoma of the bladder

Cited by 20 publications

References 21 publications

Comparative genomic profiling of glandular bladder tumours

Comparative genomic profiling of glandular bladder tumours

A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma

Practical Immunohistochemistry in Neoplastic Pathology of the Gastrointestinal Tract, Liver, Biliary Tract, and Pancreas

Contact Info

Product

Resources

About